Valisure Testimony Will Take Center Stage During Zantac Cancer Scientific Discovery
Valisure CEO David Light will tell the court how his novel online pharmacy first discovered high levels of NDMA in Zantac
Monday, October 18, 2021 - Everyone is anxiously waiting for scientific experts from both sides to testify before a Federal judge about what they know about Zantac, the leading brand of antacid medicine, causing cancer. Zantac cancer lawsuits filed around the country have been consolidated into the U.S. District Court for the Southern District of Florida, with District Judge Robin L. Rosenberg presiding. The judge has given the court more than a year after the final expert testimony slated for July 2022 to decide which experts are to testify for each side and which ones are less credible. Dauber testimony from experts could begin in May of next year (2022) and last for several months. Judges that must decide such complex scientific issues have taken six months to a year before ruling on the matter. Zantac was once the best-selling brand of heartburn and acid reflux medicine used by more than 15 million Americans per year. If ranitidine degrades to become the cancer-causing substance it is accused of being, millions of people could be walking around with undiagnosed cancer of the stomach, bladder, esophagus, colon, and prostate. Hundreds of heartburn sufferers have hired a Zantac cancer lawyer to file a claim against Sanofi, the makers of the drug for failing to warn them of what they knew or had an obligation to know about ranitidine's instability.
Zantac heartburn medicine made from ranitidine allegedly degrades naturally into N-nitrosodimethylamine (NDMA), a deadly carcinogen given to laboratory test animals to induce cancer. Experts that testify will most likely have been the ones to have conducted scientific experiments that show that ranitidine is inherently unstable and causes cancer. One expert that is sure to make waves at next year's Daubert hearings is David C. Light, the CEO of Valisure online prescription drug testing pharmacy. When the testing lab ran ranitidine through their tests they discovered levels of NDMA that were orders of magnitude greater than the level that the Food and Drug Administration considered safe. Valisure conducted a study in conjunction with experts at Stanford University. Light contacted the FDA to insist they immediately recall ranitidine from the market saying, "Valisure's research, along with that of Stanford University and others, found that NDMA was the result of the "inherent instability" of the ranitidine molecule. This means that all manufacturers, brand or generic, and all lots of ranitidine-containing medications are affected and could generate very high levels of NDMA in the human body. There's no acceptable cancer risk for a drug like this." The defense will counter that Valisure's testing methods modified the FDA's methods creating a greater amount of heat that was the cause of the NDMA spike.
In the meantime, a class-action lawsuit has been allowed to proceed against Sanofi, Pfizer, and other who sold Zatnact seeking millions of dollars to reimburse former Zantac users that require ongoing medical testing to make sure they diagnose Zantac cancer as early as possible. The companies are accused of lying to government regulators about their knowledge of ranitidine changing into the NDMA molecule.
More Recent Heartburn MedicineLawsuit News:
- Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
- Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
- Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
- The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
- Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
Lawyers for Zantac Heartburn Medicine Lawsuits
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.